Condensed interim assertion of revenue and loss for the 9 month ended 31 March 2025 (in Rupees) 2025 2024 %Change Gross sales – Internet           10,100,185,059             9,535,266,706 6% Price of Gross sales            (8,643,865,934)            (8,192,103,683) 6% Gross Revenue             1,456,319,125             1,343,163,023 8% Administrative Bills                161,904,092                154,757,727 5% Promoting Bills                119,703,970                100,497,146 19% Working Revenue             1,174,711,063             1,087,908,150 8% Monetary (Price) / Earnings               (231,505,104)               (200,800,962) 15% Different Earnings/(Loss)                165,818,206                312,952,864 -47% Different Bills                 (80,335,099)                 (82,062,737) -2% Revenue earlier than earnings taxes and ultimate tax             1,028,689,066             1,117,997,315 -8% Taxation – Ultimate taxes                           (4,004)                       (255,970) -98% Revenue earlier than earnings tax             1,028,685,062             1,117,741,345 -8% Taxation – Earnings tax               (349,842,286)               (436,344,074) -20% Revenue after earnings tax                678,842,776                681,397,271 0% Earnings per share (EPS) – Fundamental and Diluted 2.97 2.98  

#Citi #Pharma #posts #flat #9MFY25 #revenue #Rs680m


Leave a Reply

Your email address will not be published. Required fields are marked *